{"nctId":"NCT01087502","briefTitle":"Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment","startDateStruct":{"date":"2010-03"},"conditions":["Diabetes Mellitus, Type 2"],"count":241,"armGroups":[{"label":"Linagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo","Drug: Linagliptin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Glimepiride","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Glimepiride","Drug: Placebo"]}],"interventions":[{"name":"Glimepiride","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Linagliptin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Type 2 diabetes mellitus\n2. GFR\\<60 ml/min\n3. HbA1c \\>=7.0% to \\<= 10%\n4. Age \\>= 18 years\n5. BMI \\<=45 kg/m2\n6. Signed and dated written informed consent\n\nExclusion criteria:\n\n1. Myocardial infarction, stroke or TIA within 3 months prior to informed consent\n2. Renal impairment requiring dialysis\n3. Bariatric surgery\n4. Impaired hepatic function\n5. Treatment with glitazones, GLP-1 analogues, DPP-4 inhibitors\n6. Treatment with anti-obesity drugs\n7. Treatment with SU, glinides and metformin 8 weeks prior to informed consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"HbA1c Change From Baseline to Week 12","description":"HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c, renal function impairment and prior use of antidiabetic agents.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.11"},{"groupId":"OG001","value":"-0.53","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change From Baseline Over Time","description":"HbA1c is measured as a percentage. Thus, this change from baseline reflects the HbA1c percent over time minus the baseline HbA1c percent. This outcome measure only provides descriptive statistics without any modelling.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.42"},{"groupId":"OG001","value":"-0.29","spread":"0.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.68"},{"groupId":"OG001","value":"-0.47","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.79"},{"groupId":"OG001","value":"-0.50","spread":"0.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.31","spread":"0.84"},{"groupId":"OG001","value":"-0.47","spread":"0.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.48","spread":"0.88"},{"groupId":"OG001","value":"-0.48","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.51","spread":"0.93"},{"groupId":"OG001","value":"-0.52","spread":"0.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.47","spread":"0.93"},{"groupId":"OG001","value":"-0.50","spread":"0.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":"0.93"},{"groupId":"OG001","value":"-0.45","spread":"0.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.23","spread":"0.95"},{"groupId":"OG001","value":"-0.42","spread":"0.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"0.96"},{"groupId":"OG001","value":"-0.40","spread":"0.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"0.92"},{"groupId":"OG001","value":"-0.40","spread":"0.77"}]}]}]},{"type":"SECONDARY","title":"Fasting Plasma Glucose (FPG) Change From Baseline to Week 12","description":"This change from baseline reflects the Week 12 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin, week repeated within patient and week by treatment interaction.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.53","spread":"8.01"},{"groupId":"OG001","value":"0.24","spread":"7.71"}]}]}]},{"type":"SECONDARY","title":"Fasting Plasma Glucose (FPG) Change From Baseline Over Time","description":"This change from baseline reflects the FPG over time minus the baseline FPG. This outcome measure only provides descriptive statistics without any modelling.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.80","spread":"54.94"},{"groupId":"OG001","value":"-10.55","spread":"45.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.96","spread":"53.30"},{"groupId":"OG001","value":"-11.25","spread":"52.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.23","spread":"58.20"},{"groupId":"OG001","value":"-6.26","spread":"52.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.66","spread":"60.60"},{"groupId":"OG001","value":"-5.92","spread":"57.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.83","spread":"54.84"},{"groupId":"OG001","value":"-12.78","spread":"62.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.67","spread":"58.31"},{"groupId":"OG001","value":"-9.31","spread":"61.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.95","spread":"58.47"},{"groupId":"OG001","value":"-2.78","spread":"64.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.75","spread":"61.94"},{"groupId":"OG001","value":"-2.69","spread":"68.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.64","spread":"60.83"},{"groupId":"OG001","value":"-2.03","spread":"71.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.10","spread":"58.27"},{"groupId":"OG001","value":"3.09","spread":"69.03"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c <7.0%","description":"The percentage of patients with an HbA1c value below 7% at week 12 and week 52 were calculated for each treatment arm. If a patient did not have an HbA1c value at week 12 or 52 respectively, they were considered a failure, so HbA1c above 7%.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"22.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null},{"groupId":"OG001","value":"19.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c <6.5%","description":"The percentage of patients with an HbA1c value below 6.5% at week 12 and week 52 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 12 or 52 respectively they were considered a failure, so HbA1c above 6.5%.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"9.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"6.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Have a HbA1c Lowering by at Least 0.5%","description":"The percentage of patients with an HbA1c reduction of â‰¥0.5% at week 12 and week 52 from baseline was calculated for each treatment arm. If a patient did not have an HbA1c value at week 12 or 52 respectively they were considered a failure, so HbA1c reduction less than 0.5%.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":null},{"groupId":"OG001","value":"34.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":null},{"groupId":"OG001","value":"49.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of Linagliptin at Trough","description":"Trough levels of concentration of Linagliptin in plasma.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.77","spread":"36.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.62","spread":"41.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.94","spread":"107.40"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":122},"commonTop":["Hypoglycaemia","Hyperglycaemia","Nasopharyngitis","Upper respiratory tract infection","Back pain"]}}}